Startseite Serum biomarkers as early indicators of outcomes in spontaneous subarachnoid hemorrhage
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Serum biomarkers as early indicators of outcomes in spontaneous subarachnoid hemorrhage

  • Anna Maria Auricchio ORCID logo EMAIL logo , Giulia Napoli , Giovanni Maria Ceccarelli , Renata Martinelli , Grazia Menna , Marco Obersnel , Luca Scarcia , Andrea Urbani , Alessandro Olivi , Giuseppe Maria Della Pepa und Silvia Baroni
Veröffentlicht/Copyright: 28. Mai 2025
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 63 Heft 10

Abstract

Objectives

Spontaneous subarachnoid hemorrhage (sSAH) is a life-threatening neurological event with high morbidity and mortality. Predicting patient outcomes remains challenging, necessitating novel prognostic tools. This study evaluates the prognostic value of central and systemic serum biomarkers, including S100, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCHL-1), soluble suppression of tumorigenicity 2 (sST2), and soluble urokinase plasminogen activator receptor (suPAR) in acute sSAH.

Methods

A prospective observational study was conducted on 91 sSAH patients admitted to the Emergency Department. Biomarkers were measured 24 h post-admission and correlated with clinical severity using the modified Rankin Scale (mRS) at 24 h and 3 months. Statistical analyses included correlation tests, receiver operating characteristic (ROC) curves, and partial least squares discriminant analysis with 10-fold cross-validation (PLS-DA) to assess predictive accuracy.

Results

Patients with unfavorable outcomes (mRS 3–6) exhibited significantly higher median levels of all biomarkers. GFAP (ρ=0.74, p<0.0001) and S100 (ρ=0.65, p<0.0001) strongly correlated with hemorrhage volume. ROC analysis confirmed GFAP and S100 as the most effective central biomarkers (AUC=0.951), while sST2 demonstrated the highest prognostic sensitivity (97.1 %). PLS-DA further validated the prognostic relevance of sST2, GFAP, and S100.

Conclusions

Early biomarker assessment enhances sSAH prognosis, complementing neuroimaging. GFAP and S100 strongly correlate with brain injury severity, while sST2 predicts 3-months outcomes. Integrating these biomarkers into routine practice may improve early risk stratification and patient management.

Keywords: immunoassay; biomarkers; neurological disorders; chemiluminescence
Corresponding author: Anna Maria Auricchio, MD, PhD Student, Neurosurgery, 18654 University Hospital Foundation A. Gemelli IRCCS, Catholic University of the Sacred Heart, , Rome, Italy, E-mail:
Anna Maria Auricchio and Giulia Napoli contributed equally to this work.

  1. Research ethics: IRB approval obtained (FPG/ID 6185).

  2. Informed consent: Informed consent was obtained from all individuals included in this study.

  3. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: Upon reasonable request.

References

1. Claassen, J, Park, S. Spontaneous subarachnoid haemorrhage. Lancet 2022;400:846–62. https://doi.org/10.1016/s0140-6736(22)00938-2.Suche in Google Scholar

2. Duncan, IC, Terblanche, JM, Fourie, PA. Non-aneurysmal perimesencephalic subarachnoid haemorrhage with associated pontine haemorrhagic infarction. Interv Neuroradiol 2003;9:177–84. https://doi.org/10.1177/159101990300900207.Suche in Google Scholar PubMed PubMed Central

3. Wolfert, C, Maurer, CJ, Sommer, B, Steininger, K, Motov, S, Bonk, M-N, et al.. Management of perimesencephalic nonaneurysmal subarachnoid hemorrhage: a national survey. Sci Rep 2023;13:12805. https://doi.org/10.1038/s41598-023-39195-2.Suche in Google Scholar PubMed PubMed Central

4. Hoh, BL, Ko, NU, Amin-Hanjani, S, Chou, SH-Y, Cruz-Flores, S, Dangayach, NS, et al.. 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American heart association/American stroke association. Stroke. 2023;54:e314–70, https://doi.org/10.1161/str.0000000000000436.Suche in Google Scholar PubMed

5. Asikainen, A, Korja, M, Kaprio, J, Rautalin, I. Case fatality of aneurysmal subarachnoid hemorrhage varies by geographic region within Finland. Neurology 2023;101:e1950–9. https://doi.org/10.1212/wnl.0000000000207850.Suche in Google Scholar PubMed PubMed Central

6. Xia, C, Hoffman, H, Anikpezie, N, Philip, K, Wee, C, Choudhry, R, et al.. Trends in the incidence of spontaneous subarachnoid hemorrhages in the United States, 2007–2017. Neurology 2023;100:e123–32. https://doi.org/10.1212/wnl.0000000000201340.Suche in Google Scholar PubMed PubMed Central

7. Ziu, E, Khan Suheb, MZ, Mesfin, FB. Subarachnoid hemorrhage. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. [cited 2023 Dec 11]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK441958/.Suche in Google Scholar

8. Brown, RD, Broderick, JP. Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screening. Lancet Neurol 2014;13:393–404. https://doi.org/10.1016/s1474-4422(14)70015-8.Suche in Google Scholar PubMed

9. Lauzier, DC, Jayaraman, K, Yuan, JY, Diwan, D, Vellimana, AK, Osbun, JW, et al.. Early brain injury after subarachnoid hemorrhage: incidence and mechanisms. Stroke 2023;54:1426–40. https://doi.org/10.1161/strokeaha.122.040072.Suche in Google Scholar PubMed PubMed Central

10. Saver, JL, Chaisinanunkul, N, Campbell, BCV, Grotta, JC, Hill, MD, Khatri, P, et al.. Standardized nomenclature for modified Rankin scale global disability outcomes: consensus recommendations from stroke therapy academic industry roundtable XI. Stroke 2021;52:3054–62. https://doi.org/10.1161/strokeaha.121.034480.Suche in Google Scholar PubMed

11. Nobels-Janssen, E, Postma, EN, Abma, IL, van Dijk, JMC, de Ridder, IR, Schenck, H, et al.. Validity of the modified Rankin Scale in patients with aneurysmal subarachnoid hemorrhage: a randomized study. BMC Neurol 2024;24:23. https://doi.org/10.1186/s12883-023-03479-x.Suche in Google Scholar PubMed PubMed Central

12. Banks, JL, Marotta, CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007;38:1091–6. https://doi.org/10.1161/01.str.0000258355.23810.c6.Suche in Google Scholar

13. Sabatino, G, Della Pepa, GM, Scerrati, A, Maira, G, Rollo, M, Albanese, A, et al.. Anatomical variants of the basal vein of Rosenthal: prevalence in idiopathic subarachnoid hemorrhage. Acta Neurochir (Wien) 2014;156:45–51. https://doi.org/10.1007/s00701-013-1907-6.Suche in Google Scholar PubMed

14. Akeret, K, Germans, M, Sun, W, Kulcsar, Z, Regli, L. Subarachnoid hemorrhage due to flow-related dissection of the posterior-inferior cerebellar artery associated with a distal arteriovenous malformation. World Neurosurg 2019;125:44–8. https://doi.org/10.1016/j.wneu.2019.01.148.Suche in Google Scholar PubMed

15. Duffau, H, Lopes, M, Janosevic, V, Sichez, JP, Faillot, T, Capelle, L, et al.. Early rebleeding from intracranial dural arteriovenous fistulas: report of 20 cases and review of the literature. J Neurosurg 1999;90:78–84. https://doi.org/10.3171/jns.1999.90.1.0078.Suche in Google Scholar PubMed

16. Cecchini, A, Rognone, F, Bertolotti, P, Raimondi, GB. Subarachnoid hemorrhage caused by cerebral arteriovenous malformations. Importance of neuroradiological studies. Minerva Med 1986;77:1165–74.Suche in Google Scholar

17. Rohart, F, Gautier, B, Singh, A, Lê Cao, K-A. mixOmics: an R package for omics feature selection and multiple data integration. PLoS Comput Biol 2017;13:e1005752. https://doi.org/10.1371/journal.pcbi.1005752.Suche in Google Scholar PubMed PubMed Central

18. Abdulazim, A, Heilig, M, Rinkel, G, Etminan, N. Diagnosis of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage and triggers for intervention. Neurocrit Care 2023;39:311–9. https://doi.org/10.1007/s12028-023-01812-3.Suche in Google Scholar PubMed PubMed Central

19. Naidech, AM, Janjua, N, Kreiter, KT, Ostapkovich, N, Fitzsimmons, B-F, Parra, A, et al.. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. JAMA Neurol 2005. https://doi.org/10.1001/archneur.62.3.410.Suche in Google Scholar PubMed

20. Connolly, ES, Rabinstein, AA, Carhuapoma, JR, Derdeyn, CP, Dion, J, Higashida, RT, et al.. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke 2012;43:1711–37. https://doi.org/10.1161/str.0b013e3182587839.Suche in Google Scholar

21. Ghaith, HS, Nawar, AA, Gabra, MD, Abdelrahman, ME, Nafady, MH, Bahbah, EI, et al.. A literature review of traumatic brain injury biomarkers. Mol Neurobiol 2022;59:4141–58. https://doi.org/10.1007/s12035-022-02822-6.Suche in Google Scholar PubMed PubMed Central

22. Papa, L, Brophy, GM, Welch, RD, Lewis, LM, Braga, CF, Tan, CN, et al.. Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a Large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol 2016;73:551–60. https://doi.org/10.1001/jamaneurol.2016.0039.Suche in Google Scholar PubMed PubMed Central

23. Nguyen, AM, Saini, V, Hinson, HE. Blood-based biomarkers for neuroprognostication in acute brain injury. Semin Neurol 2023;43:689–98. https://doi.org/10.1055/s-0043-1775764.Suche in Google Scholar PubMed PubMed Central

24. Rezaei, O, Pakdaman, H, Gharehgozli, K, Simani, L, Vahedian-Azimi, A, Asaadi, S, et al.. S100 B: A new concept in neurocritical care. Iran J Neurol 2017;16:83–9.Suche in Google Scholar

25. Sorci, G, Bianchi, R, Riuzzi, F, Tubaro, C, Arcuri, C, Giambanco, I, et al.. S100B protein, A damage-associated molecular pattern protein in the brain and heart, and beyond. Cardiovasc Psychiatry Neurol 2010;2010:656481. https://doi.org/10.1155/2010/656481.Suche in Google Scholar PubMed PubMed Central

26. Babkina, AS, Lyubomudrov, MA, Golubev, MA, Pisarev, MV, Golubev, AM. Neuron-specific enolase-what are we measuring? Int J Mol Sci 2024;25:5040. https://doi.org/10.3390/ijms25095040.Suche in Google Scholar PubMed PubMed Central

27. Cheng, F, Yuan, Q, Yang, J, Wang, W, Liu, H. The prognostic value of serum neuron-specific enolase in traumatic brain injury: systematic review and meta-analysis. PLoS One 2014;9:e106680. https://doi.org/10.1371/journal.pone.0106680.Suche in Google Scholar PubMed PubMed Central

28. Jurga, AM, Paleczna, M, Kadluczka, J, Kuter, KZ. Beyond the GFAP-astrocyte protein markers in the brain. Biomolecules 2021;11:1361. https://doi.org/10.3390/biom11091361.Suche in Google Scholar PubMed PubMed Central

29. Thijssen, EH, Verberk, IMW, Kindermans, J, Abramian, A, Vanbrabant, J, Ball, AJ, et al.. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Alzheimers Dement (Amst) 2022;14:e12285. https://doi.org/10.1002/dad2.12285.Suche in Google Scholar PubMed PubMed Central

30. Diaz-Arrastia, R, Wang, KKW, Papa, L, Sorani, MD, Yue, JK, Puccio, AM, et al.. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma 2014;31:19–25. https://doi.org/10.1089/neu.2013.3040.Suche in Google Scholar PubMed PubMed Central

31. Bishop, P, Rocca, D, Henley, JM. Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction. Biochem J 2016;473:2453–62. https://doi.org/10.1042/bcj20160082.Suche in Google Scholar PubMed PubMed Central

32. Miller, AM, Liew, FY. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease. Pharmacol Ther 2011;131:179–86. https://doi.org/10.1016/j.pharmthera.2011.02.005.Suche in Google Scholar PubMed

33. Emdin, M, Aimo, A, Vergaro, G, Bayes-Genis, A, Lupón, J, Latini, R, et al.. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol 2018;72:2309–20. https://doi.org/10.1016/j.jacc.2018.08.2165.Suche in Google Scholar PubMed

34. Rasmussen, LJH, Petersen, JEV, Eugen-Olsen, J. Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol 2021;12:780641. https://doi.org/10.3389/fimmu.2021.780641.Suche in Google Scholar PubMed PubMed Central

35. Timmermans, K, Vaneker, M, Scheffer, GJ, Maassen, P, Janssen, S, Kox, M, et al.. Soluble urokinase-type plasminogen activator levels are related to plasma cytokine levels but have low predictive value for mortality in trauma patients. J Crit Care 2015;30:476–80. https://doi.org/10.1016/j.jcrc.2015.01.006.Suche in Google Scholar PubMed

36. Velissaris, D, Zareifopoulos, N, Karamouzos, V, Pierrakos, C, Karanikolas, M. Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: an update. Caspian J Intern Med 2022;13:650–65. https://doi.org/10.22088/cjim.13.4.650.Suche in Google Scholar PubMed PubMed Central

37. Auricchio, AM, Baroni, S, Rezai Jahromi, B, Valz Gris, A, Sturiale, CL, Ceccarelli, GM, et al.. Predicting role of GFAP and UCH-L1 biomarkers in spontaneous subarachnoid hemorrhage: a preliminary study to evaluate in the short-term their correlation with severity of bleeding and prognosis. J Clin Neurosci 2024;126:119–27. https://doi.org/10.1016/j.jocn.2024.06.003.Suche in Google Scholar PubMed

Supplementary Material

This article contains supplementary material (https://doi.org/10.1515/cclm-2025-0309).

Received: 2025-03-13
Accepted: 2025-05-14
Published Online: 2025-05-28
Published in Print: 2025-09-25

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Quality indicators: an evolving target for laboratory medicine
  4. Reviews
  5. Regulating the future of laboratory medicine: European regulatory landscape of AI-driven medical device software in laboratory medicine
  6. The spectrum of nuclear patterns with stained metaphase chromosome plate: morphology nuances, immunological associations, and clinical relevance
  7. Opinion Papers
  8. Comprehensive assessment of medical laboratory performance: a 4D model of quality, economics, velocity, and productivity indicators
  9. Detecting cardiac injury: the next generation of high-sensitivity cardiac troponins improving diagnostic outcomes
  10. Perspectives
  11. Can Theranos resurrect from its ashes?
  12. Guidelines and Recommendations
  13. Australasian guideline for the performance of sweat chloride testing 3rd edition: to support cystic fibrosis screening, diagnosis and monitoring
  14. General Clinical Chemistry and Laboratory Medicine
  15. Recommendations for the integration of standardized quality indicators for glucose point-of-care testing
  16. A cost-effective assessment for the combination of indirect immunofluorescence and solid-phase assay in ANA-screening
  17. Assessment of measurement uncertainty of immunoassays and LC-MS/MS methods for serum 25-hydroxyvitamin D
  18. A novel immunoprecipitation-based targeted liquid chromatography-tandem mass spectrometry analysis for accurate determination for copeptin in human serum
  19. Histamine metabolite to basal serum tryptase ratios in systemic mastocytosis and hereditary alpha tryptasemia using a validated LC-MS/MS approach
  20. Machine learning algorithms with body fluid parameters: an interpretable framework for malignant cell screening in cerebrospinal fluid
  21. Impact of analytical bias on machine learning models for sepsis prediction using laboratory data
  22. Immunochemical measurement of urinary free light chains and Bence Jones proteinuria
  23. Serum biomarkers as early indicators of outcomes in spontaneous subarachnoid hemorrhage
  24. High myoglobin plasma samples risk being reported as falsely low due to antigen excess – follow up after a 2-year period of using a mitigating procedure
  25. Candidate Reference Measurement Procedures and Materials
  26. Commutability evaluation of glycated albumin candidate EQA materials
  27. Reference Values and Biological Variations
  28. Health-related reference intervals for heavy metals in non-exposed young adults
  29. Hematology and Coagulation
  30. Practical handling of hemolytic, icteric and lipemic samples for coagulation testing in European laboratories. A collaborative survey from the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM)
  31. Cancer Diagnostics
  32. Assessment of atypical cells in detecting bladder cancer in female patients
  33. Cardiovascular Diseases
  34. False-positive cardiac troponin I values due to macrotroponin in healthy athletes after COVID-19
  35. Diabetes
  36. A comparison of current methods to measure antibodies in type 1 diabetes
  37. Letters to the Editor
  38. The neglected issue of pyridoxal- 5′ phosphate
  39. Error in prostate-specific antigen levels after prostate cancer treatment with radical prostatectomy
  40. Arivale is dead ‒ Hooke is alive
  41. A single dose of 20-mg of ostarine is detectable in hair
  42. Growing importance of vocabularies in medical laboratories
  43. Congress Abstracts
  44. 62nd National Congress of the Hungarian Society of Laboratory Medicine Szeged, Hungary, August 28–30, 2025
https://doi.org/10.1515/cclm-2025-0309
Schlagwörter für diesen Artikel
immunoassay; biomarkers; neurological disorders; chemiluminescence

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Quality indicators: an evolving target for laboratory medicine
  4. Reviews
  5. Regulating the future of laboratory medicine: European regulatory landscape of AI-driven medical device software in laboratory medicine
  6. The spectrum of nuclear patterns with stained metaphase chromosome plate: morphology nuances, immunological associations, and clinical relevance
  7. Opinion Papers
  8. Comprehensive assessment of medical laboratory performance: a 4D model of quality, economics, velocity, and productivity indicators
  9. Detecting cardiac injury: the next generation of high-sensitivity cardiac troponins improving diagnostic outcomes
  10. Perspectives
  11. Can Theranos resurrect from its ashes?
  12. Guidelines and Recommendations
  13. Australasian guideline for the performance of sweat chloride testing 3rd edition: to support cystic fibrosis screening, diagnosis and monitoring
  14. General Clinical Chemistry and Laboratory Medicine
  15. Recommendations for the integration of standardized quality indicators for glucose point-of-care testing
  16. A cost-effective assessment for the combination of indirect immunofluorescence and solid-phase assay in ANA-screening
  17. Assessment of measurement uncertainty of immunoassays and LC-MS/MS methods for serum 25-hydroxyvitamin D
  18. A novel immunoprecipitation-based targeted liquid chromatography-tandem mass spectrometry analysis for accurate determination for copeptin in human serum
  19. Histamine metabolite to basal serum tryptase ratios in systemic mastocytosis and hereditary alpha tryptasemia using a validated LC-MS/MS approach
  20. Machine learning algorithms with body fluid parameters: an interpretable framework for malignant cell screening in cerebrospinal fluid
  21. Impact of analytical bias on machine learning models for sepsis prediction using laboratory data
  22. Immunochemical measurement of urinary free light chains and Bence Jones proteinuria
  23. Serum biomarkers as early indicators of outcomes in spontaneous subarachnoid hemorrhage
  24. High myoglobin plasma samples risk being reported as falsely low due to antigen excess – follow up after a 2-year period of using a mitigating procedure
  25. Candidate Reference Measurement Procedures and Materials
  26. Commutability evaluation of glycated albumin candidate EQA materials
  27. Reference Values and Biological Variations
  28. Health-related reference intervals for heavy metals in non-exposed young adults
  29. Hematology and Coagulation
  30. Practical handling of hemolytic, icteric and lipemic samples for coagulation testing in European laboratories. A collaborative survey from the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM)
  31. Cancer Diagnostics
  32. Assessment of atypical cells in detecting bladder cancer in female patients
  33. Cardiovascular Diseases
  34. False-positive cardiac troponin I values due to macrotroponin in healthy athletes after COVID-19
  35. Diabetes
  36. A comparison of current methods to measure antibodies in type 1 diabetes
  37. Letters to the Editor
  38. The neglected issue of pyridoxal- 5′ phosphate
  39. Error in prostate-specific antigen levels after prostate cancer treatment with radical prostatectomy
  40. Arivale is dead ‒ Hooke is alive
  41. A single dose of 20-mg of ostarine is detectable in hair
  42. Growing importance of vocabularies in medical laboratories
  43. Congress Abstracts
  44. 62nd National Congress of the Hungarian Society of Laboratory Medicine Szeged, Hungary, August 28–30, 2025
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 10.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2025-0309/html?lang=de
Button zum nach oben scrollen